Abstract:Abstract Background To assess the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer. Methods This prospective, open-label, single-arm phase II trial enrolled patients with stage II-III breast cancer with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative. Eligible patients received tucidinostat plus exemestane, and then breast-conserving surgery (BCS) or modified radical mastectomy. Results Among 20 enrolled patients, 3 of them achieved preoperative endocrine prognostic index (PEPI) score of 0. Additionally, complete cell cycle arrest was observed in 7, radiologic objective response rate in 10, and disease control rate in 20 patients, pathological complete response in 1 patient, and 5 patients performed BCS. Ki67 suppression from baseline to surgery was observed in 17 of patients, with the Ki67 change ratio of −73.5%. Treatment-emergent adverse event included neutropenia, leukopenia, thrombocytopenia, lymphopenia, hypoalbuminemia, aspartate aminotransferase elevation, glutamyl transpeptidase elevation, anemia, and alanine aminotransferase elevation. Conclusions Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted. Clinical Trial Registration ChiCTR2100046678.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the efficacy and safety of tucidinostat combined with exemestane as a neoadjuvant treatment strategy in early - stage hormone - receptor - positive, HER2 - negative breast cancer patients. Specifically, the study aims to explore the potential of this combination therapy in terms of tumor down - staging, increasing the opportunity for surgical options, and survival benefits, while focusing on its impact on key indicators such as cell - cycle inhibition and the pathological complete response rate (pCR). ### Research Background - **Background**: Breast cancer is the most common cancer among women worldwide, and more than 70% of cases are hormone - receptor - positive breast cancer. Endocrine therapy is the standard treatment for hormone - receptor - positive breast cancer. In recent years, neoadjuvant therapy has performed well in tumor down - staging, providing patients with more surgical options and survival advantages. However, breast cancers of different molecular subtypes respond differently to neoadjuvant chemotherapy (NCT), especially the pathological complete response rate (pCR) of luminal - type breast cancer is only 10% - 20%. - **Problem**: In order to overcome endocrine resistance and improve efficacy, combining endocrine therapy with other drugs has become a common clinical strategy. Currently, most clinical trials of neoadjuvant endocrine therapy mainly focus on CDK4/6 inhibitors, but the adverse reactions of these inhibitors are relatively significant. Therefore, it is particularly important to find new effective and safe treatment regimens. ### Research Objectives - **Primary objective**: To evaluate the efficacy and safety of tucidinostat combined with exemestane as a neoadjuvant treatment in early - stage hormone - receptor - positive, HER2 - negative breast cancer patients. - **Secondary objectives**: To evaluate complete cell - cycle arrest (CCCA), pathological complete response rate (pCR), objective response rate (ORR), disease control rate (DCR), and the proportion of breast - conserving surgery (BCS), and to evaluate the safety and tolerance of the treatment. ### Methods - **Study design**: This is a prospective, single - center, open - label, single - arm phase II clinical trial, enrolling stage II - III hormone - receptor - positive, HER2 - negative breast cancer patients. - **Interventions**: Patients received oral tucidinostat (30 mg, twice a week) combined with oral exemestane (25 mg) daily for 24 weeks. Premenopausal patients also received goserelin (3.6 mg, once every 28 days, a total of 6 times). - **Assessment indicators**: The primary endpoint was the proportion of patients with a preoperative endocrine prognostic index (PEPI) score of 0. Secondary endpoints included CCCA, pCR, ORR, DCR, BCS proportion, and safety and tolerance. ### Results - **Primary results**: Among the 20 patients who completed the treatment, 3 patients had a PEPI score of 0, 10 patients had a PEPI score between 1 and 3, and 7 patients had a PEPI score of 4 or above. In addition, complete cell - cycle arrest was observed in 7 patients, 10 patients achieved an objective response on imaging, 1 patient achieved a pathological complete response, and 5 patients underwent breast - conserving surgery. - **Secondary results**: Adverse events during the treatment process included neutropenia, leukopenia, thrombocytopenia, lymphopenia, hypoproteinemia, elevated aspartate aminotransferase, elevated glutamyl transpeptidase, anemia, and elevated alanine aminotransferase. ### Discussion - **Conclusion**: Although the proportion of patients with a PEPI score of 0 is not high, tucidinostat combined with exemestane as a neoadjuvant treatment shows good tolerance and promising clinical responses in early - stage hormone - receptor - positive, HER2 - negative breast cancer patients. The results of this study suggest that this combination therapy may provide a new treatment option for these patients. - **Future directions**: Larger - scale and multi - center studies are needed to verify these results and further explore the impact of this treatment strategy on long - term prognosis. ### Clinical Significance - **Clinical application**: Although the proportion of patients with a PEPI score of 0 is not high, the neoadjuvant treatment of tucidinostat combined with exemestane shows good tolerance and promising clinical responses, and may provide a new treatment option for early - stage hormone - receptor - positive, HER2 - negative breast cancer patients. Through this study, researchers hope to be able to provide a more effective and safe treatment regimen for early - stage hormone - receptor - positive, HER2 - negative breast cancer patients, thereby improving their prognosis and quality of life.

Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer.

247P KN026 in Combination with Docetaxel As Neoadjuvant Treatment for HER2+ Early or Locally Advanced Breast Cancer (BC): A Single-Arm, Multicenter, Phase II Study

Abstract OT2-16-04: KN026 in combination with docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer: A single arm, multicenter, phase 2 study

Abstract P5-09-05: A phase II, single-arm study of histone deacetylases inhibitor Tucidinostat and Exemestane as neoadjuvant therapy in patients with hormone receptor positive HER2 negative breast cancer (NeoTEE trial)

Tucidinostat Plus Exemestane for Postmenopausal Patients with Advanced, Hormone Receptor-Positive Breast Cancer (ACE): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial

Supplementary Material For: Neoadjuvant Pyrotinib Plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced HER2-positive Breast Cancer in China: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.

Preoperative (neoadjuvant) Therapy with Tislelizumab for Locally Advanced Colorectal Cancer with High Microsatellite Instability or Deficient Mismatch Repair: an Open-Label, Single-Arm, Multicenter Phase II Study.

Neoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer: A prospective, multicenter, randomized two-group, non-controlled phase 2 clinical trial.

Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer

Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer

Analysis of Neoadjuvant Docetaxel, Carboplatin and Trastuzumab (TCH) in HER-2-positive Breast Cancer

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study

Abstract P4-14-07: Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 8–12 weeks' exemestane exposure for ER+/HER2– postmenopausal breast cancer patients

Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis

Abstract PO1-19-04: Dalpiciclib and tucidinostat in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Abstract PO4-18-04: An exploratory study of Trastuzumab Deruxtecan neoadjuvant therapy in HER2-positive or HER2-low early or locally advanced breast cancer after a poor response to neoadjuvant chemotherapy